A5013897699- Hepatitis C virus research
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Liver Disease Diagnosis and Treatment
- Diabetes and associated disorders
- SARS-CoV-2 and COVID-19 Research
- Hepatitis B Virus Studies
- Systemic Sclerosis and Related Diseases
- Viral-associated cancers and disorders
- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Kawasaki Disease and Coronary Complications
- Liver Diseases and Immunity
- Immunodeficiency and Autoimmune Disorders
- Renal Diseases and Glomerulopathies
- T-cell and B-cell Immunology
- Eosinophilic Disorders and Syndromes
- Cytokine Signaling Pathways and Interactions
- Vasculitis and related conditions
- Pancreatitis Pathology and Treatment
- Dermatological and COVID-19 studies
- Peripheral Neuropathies and Disorders
- Monoclonal and Polyclonal Antibodies Research
Sapienza University of Rome
2015-2024
Istituto Pasteur
2018
Policlinico Umberto I
2003-2016
Fondazione Roma
2016
Istituti Fisioterapici Ospitalieri
2008
Lahey Hospital and Medical Center
2002
University of Perugia
2002
Veterans Health Administration
2002
University of Pisa
1997
Edith Nourse Rogers Memorial Veterans Hospital
1997
Hepatitis C virus (HCV)‐associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon eradication, but conventional therapy with pegylated interferon and ribavirin yields approximately 40% sustained virologic responses (SVR). We prospectively evaluated the efficacy safety of sofosbuvir‐based direct‐acting antiviral therapy, individually tailored according to latest guidelines, in a cohort 44 consecutive patients HCV‐associated MC. In two MC had evolved into an indolent lymphoma...
Abstract Chronic hepatitis C virus infection causes B cell lymphoproliferative disorders that include type II mixed cryoglobulinemia and lymphoma. This drives the monoclonal expansion and, occasionally, malignant transformation of cells producing a polyreactive natural Ab commonly encoded by VH1–69 variable gene. Owing to their property Ab, these are reminiscent murine B-1 marginal zone cells. We used anti-Id Abs track stages differentiation clonal VH1–69+ in patients with cryoglobulinemia....
Hepatitis C virus (HCV)-related mixed cryoglobulinaemia vasculitis (MCV) is characterized by the expansion of rheumatoid factor-producing B-cell clones. The aim this study was to assess whether clones may persist in these patients after clearance with antiviral therapy, and their persistence influences clinical outcomes.Forty-five HCV-cured MCV were followed up for a median 18.5 (range 9-38) months HCV. Circulating detected using flow cytometry either skewing kappa/lambda ratio or expression...
A clonal population of B cells expressing a V H 1‐69‐encoded idiotype accumulates in hepatitis C virus ( HCV ) associated mixed cryoglobulinemia MC ). These are phenotypically heterogeneous, resembling either typical marginal zone MZ I g M + D CD 27 21 or the exhausted low that accumulate HIV infection common variable immunodeficiency. We show both ‐like and 1‐69 patients functionally exhausted, since they fail to respond TLR BCR ligands. The proliferative defect can be overcome by...
INTRODUCTION: Direct-acting antiviral agents (DAAs) have modified the management of chronic hepatitis C virus (HCV) infection, including HCV-related cryoglobulinemic vasculitis (CryoVas). However, patients might experience relapse, and no reliable predictors CryoVas relapse after sustained virologic response (SVR) been established. We aimed to describe HCV-CryoVas rates factors associated with it. METHODS: An international multicenter cohort where from Egypt, France, Italy treated DAA were...